Pharmafile Logo

News and Press Releases

CN Bio raises $21m in first close of Series B investment round

Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10m and $5.5m, respectively Investment will expand product development and scaling of the organisation to meet increased demand for...

Category: Biotechnology, Drug Discovery, Other
Posted: April 23, 2024

CN Bio
332 Cambridge Science Park, Milton Road Cambridge, CB4 0WN

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies 

Strategic partnership harnesses respective organ-specific expertise to provide complete human-derived Organ-on-a-Chip solution for more accurate in vitro ADME predictions   Early access to dual-organ model available through CN Bio’s Contract Research...

Category: Biotechnology
Posted: January 23, 2024

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ

CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA

Six-year collaboration recognised at prestigious awards ceremony for its continued success in advancing OOC research to support widespread adoption across the pharmaceutical industry 23 November 2023 -- Cambridge, UK --...

Category: Clinical Trials
Posted: November 23, 2023

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ